Pharma Journalist -

Allarity Therapeutics, Inc., a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer…
Read More...

Leading integrated drug discovery partner, Sygnature Discovery (“Sygnature”) has announced its acquisition of one of North America’s largest discovery Contract Research Organisations,…
Read More...

Pressing issues around care affordability and access threaten US insurance models. We must shift our focus to examining the latest research on the links between out-of-pocket spending…
Read More...

AbbVie and Calibr announced an expanded strategic collaboration to advance several innovative preclinical and early-stage clinical assets across AbbVie's core therapeutic growth areas…
Read More...

Gilead Sciences, Inc. announced that the European Commission (EC) approved Trodelvy (sacituzumab govitecan) as a monotherapy for the treatment of adult patients with unresectable or…
Read More...

InSilicoTrials, a leading provider of artificial intelligence (AI) and simulation tools for drug and medical device development, has embarked on a collaborative partnership with Axoltis…
Read More...

Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, announced the initiation…
Read More...

Ayala Pharmaceuticals, Inc. and Biosight Ltd. announced they have entered into a definitive merger agreement pursuant to which Ayala will combine with Biosight in an all-stock…
Read More...

Kriya Therapeutics, Inc. announced the addition of over $150 million in capital committed as part of its Series C Financing, bringing the total Series C round to over $430 million.…
Read More...

LianBio’s partner, Tarsus Pharmaceuticals (Tarsus), announced yesterday that the U.S. Food and Drug Administration (FDA) approved XDEMVY (lotlilaner ophthalmic solution) 0.25% for the…
Read More...